UNS unilife corporation

Co. Website., page-49

  1. 2,957 Posts.
    lightbulb Created with Sketch. 511
    More comfort reading

    Britain's medicines regulator has granted dupilumab a positive scientific opinion through its Early Access to Medicines Scheme, meaning patients can get the drug before it is granted formal marketing authorisation, Sanofi said on Tuesday.
    Dupilumab has impressed doctors in a series of clinical trials over the past year and consensus analyst forecasts already point to annual global sales of more than $4 billion by 2022

    http://uk.reuters.com/article/uk-sanofi-fr-regeneron-eczema-britain-idUKKBN16L0VF
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.